Kind Intelligence Foundry’s first product, Glo, is an SMS-based AI companion for people on GLP-1 medications such as Ozempic, Wegovy, Zepbound, and Mounjaro, now available in alpha at askglo.ai
SAN FRANCISCO, CA / ACCESS Newswire / March 24, 2026 / Today, Innit announced the spin-off Kind Intelligence Foundry (K.I. Foundry, Inc.), a new independent, consumer-focused venture dedicated to developing AI health companions that help people navigate everyday health challenges with personalized, empathetic support.
The spin-off marks Innit’s expansion into direct-to-consumer digital health, building on years of work developing B2B personalized health platforms with leading global partners.
The new company’s first product, Glo, is an SMS-based AI companion designed to support people taking GLP-1 medications such as Ozempic, Wegovy, Zepbound and Mounjaro. As millions of people begin these therapies, many encounter practical day-to-day questions around nutrition, side effects, and lifestyle changes between doctor visits.
Glo meets users where they already are – via a simple text message – providing personalized guidance, encouragement, and daily coaching to help them stay on track. The product is currently available in alpha at askglo.ai.
Kind Intelligence Foundry is led by CEO Stathis Mytilinaios, who joined Innit as COO and led the development of its platform in partnership with leading retailers, food companies, and appliance manufacturers. During his time at Innit, he also led the development of Phil, the first Type 2 diabetes companion application of its kind created in partnership with Roche, designed to provide personalized daily support for people managing diabetes.
Prior to joining Innit, Mytilinaios was part of the founding team at Livongo Health, where he helped build an FDA-cleared digital health platform that grew to serve millions of people before its $18.5 billion acquisition by Teladoc Health.
Eugenio Minvielle, founder of Innit, said: “Stathis built something exceptional at Innit, including the development of our modular platform and Phil with Roche. This spin-off enables him to bring AI companions directly to consumers. Kind Intelligence Foundry is ready to operate independently, and I’m excited to see the meaningful and lasting impact it will have on people’s health and daily lives as they launch Glo and new solutions to market.¨
Stathis Mytilinaios, CEO of Kind Intelligence Foundry, added: “Millions of people are starting GLP-1 medications with real questions and often no one to turn to between doctor visits. Glo meets them where they already are, in a text message, with coaching that is personal, judgment-free, and always available. Our goal is to put all the chances on their side for a successful journey, make it fun along the way, and build a community of like-minded people going through similar experiences.”
About Innit
Innit develops solutions at the intersection of food and health, combining data, artificial intelligence, and consumer experiences to simplify everyday decisions and improve daily life. Innit will continue to operate its enterprise B2B platform, technology IP, and global partnerships as an independent business. Visit http://www.innit.com.
About Kind Intelligence Foundry
Kind Intelligence Foundry (K.I. Foundry, Inc.) builds AI companions for everyday health directly to consumers. Its first product, Glo, is an SMS-first AI companion designed for people taking GLP-1 medications. kindintelligence.ai
Media Contact: Stathis Mytilinaios, CEO Kind Intelligence Foundry [email protected]
SOURCE: Innit International
Related Documents:
